Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy
in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in
levodopa-treated PD patients with motor fluctuations.
The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety
of rasagiline compared to placebo in Chinese PD patients not treated with levodopa.